Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL BONE MARROW MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL BONE MARROW MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET GUIDE
2.2.4 COMPANY POSITIONING GRID
2.2.5 COMPANY MARKET SHARE ANALYSIS
2.2.6 MULTIVARIATE MODELLING
2.2.7 TOP TO BOTTOM ANALYSIS
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 VENDOR SHARE ANALYSIS
2.2.10 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.11 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL BONE MARROW MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
5.3 IN-DEPTH ANALYSIS OF OPERATIONAL TECNIQUES, BY COUNTRY
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 COST ANALYSIS BREAKDOWN
8 TECHNONLOGY ROADMAP
9 INNOVATION TRACKER AND STRATEGIC ANALYSIS
9.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
9.1.1 JOINT VENTURES
9.1.2 MERGERS AND ACQUISITIONS
9.1.3 LICENSING AND PARTNERSHIP
9.1.4 TECHNOLOGY COLLABORATIONS
9.1.5 STRATEGIC DIVESTMENTS
9.2 NUMBER OF PRODUCTS IN DEVELOPMENT
9.3 STAGE OF DEVELOPMENT
9.4 TIMELINES AND MILESTONES
9.5 INNOVATION STRATEGIES AND METHODOLOGIES
9.6 RISK ASSESSMENT AND MITIGATION
9.7 FUTURE OUTLOOK
10 REGULATORY COMPLIANCE
10.1 REGULATORY AUTHORITIES
10.2 REGULATORY CLASSIFICATIONS
10.2.1 CLASS I
10.2.2 CLASS II
10.2.3 CLASS III
10.3 REGULATORY SUBMISSIONS
10.4 INTERNATIONAL HARMONIZATION
10.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
10.6 REGULATORY CHALLENGES AND STRATEGIES
11 REIMBURSEMENT FRAMEWORK
12 VALUE CHAIN ANALYSIS
13 HEALTHCARE ECONOMY
13.1 HEALTHCARE EXPENDITURE
13.2 CAPITAL EXPENDITURE
13.3 CAPEX TRENDS
13.4 CAPEX ALLOCATION
13.5 FUNDING SOURCES
13.6 INDUSTRY BENCHMARKS
13.7 GDP RATION IN OVERALL GDP
13.8 HEALTHCARE SYSTEM STRUCTURE
13.9 GOVERNMENT POLICIES
13.1 ECONOMIC DEVELOPMENT
14 GLOBAL BONE MARROW MARKET, BY TYPE
14.1 OVERVIEW
14.2 AUTOLOGOUS TRANSPLANTATION
14.3 ALLOGENEIC TRANSPLANTATION
14.4 OTHERS
15 GLOBAL BONE MARROW MARKET, BY DIAGNOSIS TEST
15.1 OVERVIEW
15.2 BONE MARROW BIOPSY
15.3 BONE MARROW ASPIRATION
15.4 OTHERS
16 GLOBAL BONE MARROW MARKET, BY PRODUCT
16.1 OVERVIEW
16.2 DEVICES
16.2.1 DIAGNOSTIC
16.2.2 FULL-FIELD BONE MARROW ASPIRATE
16.2.3 BONE MARROW BIOPSY AND ASPIRATION NEEDLES
16.2.4 OTHERS
16.2.5 COLLECTION
16.2.6 BONE MARROW CONCENTRATOR
16.2.7 BONE MARROW PROCESSING SYSTEM
16.2.8 OTHERS
16.3 BONE MARROW-DERIVED PRODUCTS
16.3.1 CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCS)
16.3.2 BONE MARROW ASPIRATE CONCENTRATE (BMAC)
16.3.3 MESENCHYMAL STEM CELLS (MSCS)
16.4 OTHERS
17 GLOBAL BONE MARROW MARKET, BY POPULATION TYPE
17.1 OVERVIEW
17.2 PEDIATRIC
17.3 ADULT
17.4 GERIATRIC
18 GLOBAL BONE MARROW MARKET, BY GENDER
18.1 OVERVIEW
18.2 MALE
18.2.1 PEDIATRIC
18.2.2 ADULT
18.2.3 GERIATRIC
18.3 FEMALE
18.3.1 PEDIATRIC
18.3.2 ADULT
18.3.3 GERIATRIC
19 GLOBAL BONE MARROW MARKET, BY APPLICATION
19.1 OVERVIEW
19.2 LYMPHOMA
19.3 LEUKEMIA
19.4 MYELOMA
19.5 MYELODYSPLASIA
19.6 APLASTIC ANEMIA
19.7 SICKLE CELL ANEMIA
19.8 SOLID TUMORS
19.9 THALASSEMIA
19.1 MYELOPROLIFERATIVE NEOPLASMS
19.11 OTHERS
20 GLOBAL BONE MARROW MARKET, BY END USER
20.1 OVERVIEW
20.2 HOSPITALS
20.2.1 PUBLIC
20.2.2 PRIVATE
20.3 ONCOLOGICAL CENTRES
20.4 MULTI-SPECIALTY CLINICS
20.5 ACADEMIC AND RESEARCH INSTITUTE
20.6 OTHERS
21 GLOBAL BONE MARROW MARKET, BY DISTRIBUTION CHANNEL
21.1 OVERVIEW
21.2 DIRECT TENDER
21.3 THIRD PARTY DISTRIBUTION
21.4 OTHERS
22 GLOBAL BONE MARROW MARKET, BY REGION
Global Bone Marrow Market, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
22.1 NORTH AMERICA
22.1.1 U.S.
22.1.2 CANADA
22.1.3 MEXICO
22.2 EUROPE
22.2.1 GERMANY
22.2.2 FRANCE
22.2.3 U.K.
22.2.4 FINLAND
22.2.5 DENMARK
22.2.6 NORWAY
22.2.7 POLAND
22.2.8 ITALY
22.2.9 SPAIN
22.2.10 RUSSIA
22.2.11 TURKEY
22.2.12 BELGIUM
22.2.13 NETHERLANDS
22.2.14 SWITZERLAND
22.2.15 SWEDEN
22.2.16 REST OF EUROPE
22.3 ASIA-PACIFIC
22.3.1 JAPAN
22.3.2 CHINA
22.3.3 SOUTH KOREA
22.3.4 INDIA
22.3.5 SINGAPORE
22.3.6 THAILAND
22.3.7 INDONESIA
22.3.8 MALAYSIA
22.3.9 PHILIPPINES
22.3.10 AUSTRALIA
22.3.11 NEW ZEALAND
22.3.12 VIETNAM
22.3.13 TAIWAN
22.3.14 REST OF ASIA-PACIFIC
22.4 SOUTH AMERICA
22.4.1 BRZIL
22.4.2 ARGENTINA
22.4.3 REST OF SOUTH AMERICA
22.5 MIDDLE EAST AND AFRICA
22.5.1 SOUTH AFRICA
22.5.2 SAUDI ARABIA
22.5.3 UAE
22.5.4 EGYPT
22.5.5 KUWAIT
22.5.6 OMAN
22.5.7 ISRAEL
22.5.8 BAHRAIN
22.5.9 REST OF MIDDLE EAST AND AFRICA
22.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
23 GLOBAL BONE MARROW MARKET, COMPANY LANDSCAPE
23.1 COMPANY SHARE ANALYSIS: GLOBAL
23.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
23.3 COMPANY SHARE ANALYSIS: EUROPE
23.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
23.5 MERGERS & ACQUISITIONS
23.6 EXPANSIONS
23.7 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
24 GLOBAL BONE MARROW MARKET, SWOT AND DBMR ANALYSIS
25 GLOBAL BONE MARROW MARKET, COMPANY PROFILE
25.1 CHARLES RIVER LABORATORIES
25.1.1 COMPANY OVERVIEW
25.1.2 GEOGRAPHIC PRESENCE
25.1.3 PRODUCT PORTFOLIO
25.1.4 RECENT DEVELOPMENTS
25.2 ATCC
25.2.1 COMPANY OVERVIEW
25.2.2 GEOGRAPHIC PRESENCE
25.2.3 PRODUCT PORTFOLIO
25.2.4 RECENT DEVELOPMENTS
25.3 KOSHEEKA
25.3.1 COMPANY OVERVIEW
25.3.2 GEOGRAPHIC PRESENCE
25.3.3 PRODUCT PORTFOLIO
25.3.4 RECENT DEVELOPMENTS
25.4 STEMCELL TECHNOLOGIES
25.4.1 COMPANY OVERVIEW
25.4.2 GEOGRAPHIC PRESENCE
25.4.3 PRODUCT PORTFOLIO
25.4.4 RECENT DEVELOPMENTS
25.5 LONZA
25.5.1 COMPANY OVERVIEW
25.5.2 GEOGRAPHIC PRESENCE
25.5.3 PRODUCT PORTFOLIO
25.5.4 RECENT DEVELOPMENTS
25.6 ACCEGEN
25.6.1 COMPANY OVERVIEW
25.6.2 GEOGRAPHIC PRESENCE
25.6.3 PRODUCT PORTFOLIO
25.6.4 RECENT DEVELOPMENTS
25.7 ALLCELLS, LLC
25.7.1 COMPANY OVERVIEW
25.7.2 GEOGRAPHIC PRESENCE
25.7.3 PRODUCT PORTFOLIO
25.7.4 RECENT DEVELOPMENTS
25.8 ZIMMER BIOMET
25.8.1 COMPANY OVERVIEW
25.8.2 GEOGRAPHIC PRESENCE
25.8.3 PRODUCT PORTFOLIO
25.8.4 RECENT DEVELOPMENTS
25.9 HUMANCELLS BIO
25.9.1 COMPANY OVERVIEW
25.9.2 GEOGRAPHIC PRESENCE
25.9.3 PRODUCT PORTFOLIO
25.9.4 RECENT DEVELOPMENTS
25.1 MERCK KGAA
25.10.1 COMPANY OVERVIEW
25.10.2 GEOGRAPHIC PRESENCE
25.10.3 PRODUCT PORTFOLIO
25.10.4 RECENT DEVELOPMENTS
25.11 BIOIVT LLC.
25.11.1 COMPANY OVERVIEW
25.11.2 GEOGRAPHIC PRESENCE
25.11.3 PRODUCT PORTFOLIO
25.11.4 RECENT DEVELOPMENTS
25.12 CGT GLOBAL.
25.12.1 COMPANY OVERVIEW
25.12.2 GEOGRAPHIC PRESENCE
25.12.3 PRODUCT PORTFOLIO
25.12.4 RECENT DEVELOPMENTS
25.13 LIFELINE CELL TECHNOLOGY
25.13.1 COMPANY OVERVIEW
25.13.2 GEOGRAPHIC PRESENCE
25.13.3 PRODUCT PORTFOLIO
25.13.4 RECENT DEVELOPMENTS
25.14 SCIENCELL RESEARCH LABORATORIES, INC
25.14.1 COMPANY OVERVIEW
25.14.2 GEOGRAPHIC PRESENCE
25.14.3 PRODUCT PORTFOLIO
25.14.4 RECENT DEVELOPMENTS
25.15 GLOBUS MEDICAL
25.15.1 COMPANY OVERVIEW
25.15.2 GEOGRAPHIC PRESENCE
25.15.3 PRODUCT PORTFOLIO
25.15.4 RECENT DEVELOPMENTS
25.16 EMCYTE CORPORATION
25.16.1 COMPANY OVERVIEW
25.16.2 GEOGRAPHIC PRESENCE
25.16.3 PRODUCT PORTFOLIO
25.16.4 RECENT DEVELOPMENTS
25.17 STRYKER
25.17.1 COMPANY OVERVIEW
25.17.2 GEOGRAPHIC PRESENCE
25.17.3 PRODUCT PORTFOLIO
25.17.4 RECENT DEVELOPMENTS
25.18 ISTO BIOLOGICS
25.18.1 COMPANY OVERVIEW
25.18.2 GEOGRAPHIC PRESENCE
25.18.3 PRODUCT PORTFOLIO
25.18.4 RECENT DEVELOPMENTS
25.19 RANFAC
25.19.1 COMPANY OVERVIEW
25.19.2 GEOGRAPHIC PRESENCE
25.19.3 PRODUCT PORTFOLIO
25.19.4 RECENT DEVELOPMENTS
25.2 ROYAL BIOLOGICS
25.20.1 COMPANY OVERVIEW
25.20.2 GEOGRAPHIC PRESENCE
25.20.3 PRODUCT PORTFOLIO
25.20.4 RECENT DEVELOPMENTS
25.21 ARTHREX, INC
25.21.1 COMPANY OVERVIEW
25.21.2 GEOGRAPHIC PRESENCE
25.21.3 PRODUCT PORTFOLIO
25.21.4 RECENT DEVELOPMENTS
25.22 TERUMO BCT, INC
25.22.1 COMPANY OVERVIEW
25.22.2 GEOGRAPHIC PRESENCE
25.22.3 PRODUCT PORTFOLIO
25.22.4 RECENT DEVELOPMENTS
25.23 FENWELL + BAXTER
25.23.1 COMPANY OVERVIEW
25.23.2 GEOGRAPHIC PRESENCE
25.23.3 PRODUCT PORTFOLIO
25.23.4 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
26 RELATED REPORTS
27 QUESTIONNAIRE
28 ABOUT DATA BRIDGE MARKET RESEARCH
